EMA/261748/2015 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
26 February 2015 
Medicinal product  
Humira/ adalimumab 
Pharmaceutical form: 
See Annex A of the CHMP Opinion 
Strengths: 
Route of administration: 
See Annex A 
See Annex A 
Packaging and package sizes: 
See Annex A 
Numbers in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  AbbVie Ltd. 
Maidenhead, SL6 4XE 
United Kingdom 
Procedure  
Procedure number: 
EMEA/H/C/000481/II/0134 
Further to the compliance check performed under Article 23 of Regulation EC No. 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0324/2013. For the purpose of the application of Article 45(3) of Regulation EC (No 1901/2006, 
significant studies in the agreed paediatric investigation plan P/0324/2013 have been completed after 
the entry into force of that Regulation,  
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with 
this agreed paediatric investigation plan.  
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
  
